Boehringer Ingelheim & Cancer Care is Personal | Boehringer Ingelheim
Cancer
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches.
Our Approach to Oncology
We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.
Cancer is One of Humanity’s Greatest Challenges
Oncology has one of the highest unmet needs in the entire healthcare industry. Despite treatment advances, people are still dying from cancer earlier than they should.
[Read more](/content/human-health/cancer/cancer-one-humanitys-greatest-challenges "Teaser headline Cancer is One of Humanity’s Greatest Challenges"/index.html)
“My ultimate goal is to cure cancer”
Norbert Kraut, Senior Executive Scientist in Discovery Research, shares how we are advancing science to bring new treatments for people with cancer.
[Read more](/content/science-innovation/human-health-innovation/science-stories/my-ultimate-goal-cure-cancer "Teaser headline “My ultimate goal is to cure cancer”"/index.html)
[High-grade neuroendocrine carcinoma: biology, unmet needs, and DLL3 biomarker in epNEC & SCLC](/content/human-health/cancer/high-grade-neuroendocrine-carcinoma-biology-unmet-needs-and-dll3-biomarker-epnec-sclc "High-grade neuroendocrine carcinoma: biology, unmet needs, and DLL3 biomarker in epNEC & SCLC"/index.html)
Boehringer Ingelheim & Cancer Care is Personal
High-grade neuroendocrine carcinoma: biology, unmet needs, and DLL3 biomarker in epNEC & SCLC
Extrapulmonary neuroendocrine carcinoma (epNEC) and small cell lung cancer (SCLC) remain among the most aggressive malignancies. Read to learn more from our experts.
[Why biomarker testing matters in cancer care](/content/human-health/cancer/why-biomarker-testing-matters-cancer-care "Why biomarker testing matters in cancer care"/index.html)
Boehringer Ingelheim & Cancer Care is Personal
Why biomarker testing matters in cancer care
Learn how biomarker testing helps make informed decisions in cancer care and find answers to the most relevant questions.
epNEC: a rare and aggressive cancer explained
Boehringer Ingelheim & Cancer Care is Personal
epNEC: a rare and aggressive cancer explained
Experts discuss the realities of extrapulmonary neuroendocrine carcinoma
[Load more](/content/human-health/cancer?page=1 "Go to next page"/index.html)
Collaborations
When it comes to winning the fight against cancer, we’re brighter together. Collaboration is fundamental to unraveling the complexities of cancer and developing breakthrough treatments with demonstrable value. As an oncology partner of choice, we are involved in long-term collaborations with many of the world’s leading academic, industry and advocacy organizations. Our approach is grounded in mutual trust, shared goals and a passion for leading science.
Working together with our collaboration partners, Boehringer Ingelheim is leading the way in the search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities in oncology and cancer immunology.